Stock Analysis
- Finland
- /
- Life Sciences
- /
- HLSE:NANOFH
Nanoform Finland Oyj Full Year 2023 Earnings: Revenues Disappoint
Nanoform Finland Oyj (HEL:NANOFH) Full Year 2023 Results
Key Financial Results
- Net loss: €20.8m (loss narrowed by 6.0% from FY 2022).
- €0.26 loss per share (improved from €0.29 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nanoform Finland Oyj Earnings Insights
Looking ahead, revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Performance of the market in Finland.
The company's shares are up 2.0% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Nanoform Finland Oyj (including 1 which makes us a bit uncomfortable).
Valuation is complex, but we're helping make it simple.
Find out whether Nanoform Finland Oyj is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About HLSE:NANOFH
Nanoform Finland Oyj
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States.
Excellent balance sheet and slightly overvalued.